Parkinson's Disease

Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon
Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon
BioSpace
Cerevel Therapeutics
Parkinson's Disease
tavapadon
Bain Capital
Novaquest
Flag link:
A busy year ahead for Parkinson’s disease
A busy year ahead for Parkinson’s disease
EP Vantage
Parkinson's Disease
drug development
AstraZeneca
Roche
Prothena
MeiraGTx
Annovis Bio
Sanofi
Alkahest
Peptron
SAGE Therapeutics
Flag link:
AbbVie to Fund Mitokinin's Parkinson Research with Option to Buy
AbbVie to Fund Mitokinin's Parkinson Research with Option to Buy
BioSpace
AbbVie
Parkinson's Disease
Mitokinin
Flag link:
Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings
Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings
Endpoints
Sanofi
earnings
Parkinson's Disease
drug development
Flag link:
Neurocrine Terminates Parkinson's Deal with Voyager Following Clinical Hold
Neurocrine Terminates Parkinson's Deal with Voyager Following Clinical Hold
BioSpace
Voyager Therapeutics
Parkinson's Disease
Neurocrine
clinical trials
Flag link:
Biogen tosses out Parkinson's hopeful cinpanemab, pays $75M for its syn
Biogen tosses out Parkinson's hopeful cinpanemab, pays $75M for its syn
Fierce Biotech
Biogen
earnings
Parkinson's Disease
cinpanemab
Flag link:
Medtronic Enrolls 1st Patient in Parkinson’s Disease Study
Medtronic Enrolls 1st Patient in Parkinson’s Disease Study
Medical Devices and Diagnostics Industry
Medtronic
Percept PC
Parkinson's Disease
devices
Flag link:
FDA hits Supernus with double whammy, handing biotech a CRL and RTF on same day
FDA hits Supernus with double whammy, handing biotech a CRL and RTF on same day
Endpoints
Supernus
FDA
SPN-812
ADHD
SPN-830
Parkinson's Disease
Flag link:
Roche buys into Prothena... kind of
Roche buys into Prothena... kind of
EP Vantage
Roche
Prothena
prasinezumab
Parkinson's Disease
Flag link:
Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M fo
Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M fo
Endpoints
Athira Pharma
IPOs
Alzheimer's disease
Parkinson's Disease
Flag link:
Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease
Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease
Yahoo/Reuters
Neurocrine Biosciences
drug launches
Parkinson's Disease
pandemic
COVID-19
Ogentys
Flag link:
Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration
Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration
Marketwatch
Denali Therapeutics
Biogen
Parkinson's Disease
Flag link:
AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts
AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts
Fierce Biotech
AbbVie
Alzheimer's disease
Parkinson's Disease
Voyager Therapeutics
Flag link:
One-and-done gene therapy wipes out Parkinson's symptoms in mouse models
One-and-done gene therapy wipes out Parkinson's symptoms in mouse models
Fierce Biotech
USCD
Parkinson's Disease
gene therapy
Flag link:
Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
Xconomy
Sunovion
FDA
Parkinson's Disease
Kynmobi
Flag link:
Pandemic Delays Neurocrine’s Drug Launch for Parkinson’s Disease
Pandemic Delays Neurocrine’s Drug Launch for Parkinson’s Disease
BioSpace
Neurocrine
drug launches
Ongentys
Parkinson's Disease
pandemic
COVID-19
Flag link:
Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
Endpoints
Acadia Pharma
Vanderbilt
Nuplazid
drug development
Alzheimer's disease
Parkinson's Disease
Flag link:
Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure
Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure
Endpoints
Novartis
ResTORbio
M&A
Parkinson's Disease
Adicet Bio
Flag link:
FDA Approves Neurocrine Biosciences' Parkinson's Drug
FDA Approves Neurocrine Biosciences' Parkinson's Drug
Motley Fool
Neurocrine
FDA
Ongentys
Parkinson's Disease
Flag link:
Coronavirus puts on hold launch plans for Neurocrine's Parkinson's drug
Coronavirus puts on hold launch plans for Neurocrine's Parkinson's drug
Biopharma Dive
Neurocrine
Parkinson's Disease
drug launches
COVID-19
pandemic
Flag link:

Pages